This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
K562 Cells
|
|
Concept
|
Bone Marrow Cells
|
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
|
Concept
|
Plasma Cells
|
|
Concept
|
Lymphoma, B-Cell, Marginal Zone
|
|
Academic Article
|
A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH.
|
|
Academic Article
|
Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes.
|
|
Academic Article
|
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
|
|
Academic Article
|
Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation.
|
|
Academic Article
|
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
|
|
Academic Article
|
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
|
|
Academic Article
|
Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.
|
|
Academic Article
|
Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab.
|
|
Academic Article
|
GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.
|
|
Academic Article
|
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
|
|
Academic Article
|
A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder.
|
|
Academic Article
|
Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.
|
|
Academic Article
|
Impact of cachexia on outcomes in aggressive lymphomas.
|
|
Academic Article
|
Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.
|
|
Academic Article
|
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
|
|
Academic Article
|
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
|
|
Academic Article
|
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
|
|
Academic Article
|
Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia.
|